Response to: Letter to the Editor From Fitzpatrick et al: “Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?”-Reference-Cited by-同舟云学术

Response to: Letter to the Editor From Fitzpatrick et al: “Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?”

Published:2024-07-15 Issue: Volume: Page:
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Grassi Giorgia¹^ORCID,Ghielmetti Alberto²,Zampogna Marta²,Chiodini Iacopo³⁴^ORCID,Arosio Maura¹²^ORCID,Mantovani Giovanna¹²^ORCID,Eller-Vainicher Cristina¹

Affiliation:

1. Endocrine Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico , 20122 Milan , Italy

2. Department of Clinical Sciences and Community Health, University of Milan , 20100 Milan , Italy

3. Department of Medical Biotechnology and Translational Medicine, University of Milan , 20100 Milan , Italy

4. Unit of Endocrinology, ASST Grande Ospedale Metropolitano Niguarda , 20162 Milan , Italy

Publisher

The Endocrine Society

Link

https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae493/58631690/dgae493.pdf

Reference7 articles.

1. Letter to the editor from fitzpatrick et al: “zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?”;Fitzpatrick;J Clin Endocrinol Metab,2024

2. Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?;Grassi;J Clin Endocrinol Metab,2024

3. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses;Cosman;J Bone Miner Res,2022

4. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence;Grassi;Eur J Endocrinol,2021

5. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS;Tsourdi;J Clin Endocrinol Metab,2021